Triple-Negative Breast Cancer: Understanding the Molecular Complexity of a Challenging Disease

Table of Contents

• Key Points
• Introduction: Why This Research Matters
• Understanding Breast Cancer Subtypes
• What Makes Triple-Negative Breast Cancer Different?
• The Six Molecular Subtypes of TNBC
• The Crucial Role of BRCA1 and BRCA2 Mutations
• DNA Repair Defects: Homologous Recombination Deficiency
• The Immune System's Role: Immune-Suppressed vs. Immune-Activated Tumors
• How TNBC Spreads: The Mesenchymal Subtype
• The LAR Subtype: When Androgen Receptors Drive Cancer
• Key Genetic Mutations and Genomic Alterations
• PARP Inhibitors: A Targeted Treatment Approach
• Clinical Implications: What This Means for Patients
• Limitations of Current Knowledge
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• TNBC lacks estrogen, progesterone, and HER2 receptors, making hormone therapy ineffective and chemotherapy the main systemic treatment.
• Genetic testing for BRCA1/BRCA2 mutations is essential because 85% of TNBC cases occur with BRCA1 germline mutations.
• TNBC has six molecular subtypes with different behaviors and potential targeted therapy options, including anti-androgen drugs for LAR subtype.
• PARP inhibitors like olaparib and talazoparib are approved for BRCA-mutated breast cancer, especially advanced or metastatic cases.
• The basal-like immune-suppressed (BLIS) subtype may not respond well to immunotherapy, while immune-activated subtypes like BL2 may be more sensitive.

Introduction: Why This Research Matters

Breast cancer (BC) is one of the most common cancers in women worldwide, and it is responsible for the highest number of cancer-related deaths among women. Not all breast cancers behave the same way, though. Some respond well to hormone-based therapies, while others are far more aggressive and difficult to treat. This review article, published in the journal Diagnostics in 2024, focuses on the most challenging subtype: triple-negative breast cancer (TNBC).

The researchers set out to provide a comprehensive overview of the molecular "particularities" — the genetic and cellular features — that make TNBC so difficult to manage. Their work is a review, meaning it synthesizes findings from many earlier studies rather than presenting new laboratory experiments. Understanding these molecular details is essential for developing better treatments and improving outcomes for patients facing this diagnosis.

This article matters because TNBC patients face unique challenges: the disease tends to be more aggressive, has fewer treatment options compared to hormone-positive breast cancers, and has a higher risk of recurrence and metastasis (spread to other parts of the body). By unraveling the molecular underpinnings of TNBC, researchers hope to identify new targets for therapy and refine how existing treatments are used.

Understanding Breast Cancer Subtypes

Breast cancer is not a single disease. The 2013 St. Gallen International Breast Cancer Conference established a classification system based on the molecular patterns of tumors, which doctors still use today to guide treatment decisions. These subtypes are determined by the presence or absence of specific receptors — proteins on the surface of cancer cells that respond to hormones or growth factors.

The main molecular subtypes of breast cancer are:

• Luminal A (estrogen receptor/progesterone receptor positive [ER/PR+], HER2 negative [HER2−], Ki67 index less than 20%): The most common and generally slowest-growing type
• Luminal B (ER/PR+ with less than 20% staining, HER2−, Ki67 index 20% or higher): Faster-growing than Luminal A
• HER2+ B2 (ER/PR+, HER2 overexpression): Driven by the HER2 growth-promoting protein
• HER2 overexpression (ER−, PR−, HER2 overexpression): HER2-positive but hormone receptor-negative
• Basal-like triple-negative breast cancer (TNBC) (ER−, PR−, HER2−): Lacks all three receptors, making it unresponsive to hormone therapy and HER2-targeted drugs
• Other special subtypes: Less common forms with distinct characteristics

The percentages listed (such as Ki67+ less than 20% vs. 20% or higher) refer to immunohistochemical staining results — a laboratory technique that measures the proportion of cells actively dividing. A higher Ki67 percentage means the tumor is proliferating more rapidly.

TNBC shows an overlapping gene expression profile with basal-like breast cancer in 60–90% of cases, meaning these two classifications are closely related but not identical. This overlap is why the terms are sometimes used interchangeably, though technically they describe different classification systems.

What Makes Triple-Negative Breast Cancer Different?

Triple-negative breast cancer is widely regarded as a highly invasive form of breast cancer. Compared to other breast cancer subtypes, TNBC is characterized by shorter survival times, higher mortality rates, and increased risks of recurrence and metastasis. This aggressive behavior is driven by the tumor's underlying biology — the very molecular features that this review explores in depth.

One of the most important facts about TNBC is its response to treatment. Chemotherapy is the main systemic treatment for TNBC because these tumors show no response to endocrine (hormone) therapy. This is because TNBC cells lack estrogen and progesterone receptors, which are the targets of hormone-blocking medications like tamoxifen or aromatase inhibitors.

The standard approach to breast cancer management in women typically includes neoadjuvant chemotherapy (chemotherapy given before surgery, often involving targeted agents), followed by conservative (breast-sparing) surgery, and then adjuvant radiotherapy (radiation after surgery) with or without additional chemotherapy and/or endocrine therapy. Radiotherapy reduces the rate of local recurrence and, as a result, the specific mortality from the disease.

Surgical options include total mastectomy (removal of the entire breast) or breast-conserving surgery. Sentinel lymph node biopsy and/or axillary lymph node dissection (removing and examining lymph nodes under the arm) are performed based on clinical guidelines for managing the axilla — though these guidelines continue to evolve as new evidence emerges.

An important epidemiological observation is that Hispanic and African-American women have a higher proportion of TNBC cases compared to Caucasian women, although it remains unclear whether TNBC molecular subtypes are linked to differences in clinical outcomes across races and ethnicities. This disparity highlights the need for diverse representation in research and culturally tailored approaches to care.

The Six Molecular Subtypes of TNBC

Even within TNBC, there is remarkable diversity. Gene expression profiling — a technique that measures which genes are turned on or off in tumor tissue — has categorized TNBC into six distinct subtypes. Each subtype has its own molecular fingerprint, behavior patterns, and potential treatment responses:

1. Basal-like 1 (BL1): Characterized by expression of genes regulating the cell cycle and response to DNA damage. These tumors tend to be highly proliferative (cells divide and grow rapidly), which may make them more responsive to chemotherapy regimens that target rapidly dividing cells.
2. Basal-like 2 (BL2): Associated with immune system-related gene expression, often showing signs of immune cell infiltration within the tumor microenvironment. This subtype may have a more pronounced immune response, potentially making it more sensitive to immunotherapy approaches.
3. Mesenchymal (M): Defined by gene expression patterns resembling connective tissue cells, with features of epithelial-mesenchymal transition (EMT) — a process where cancer cells transform from a stationary state to a mobile, invasive one.
4. Mesenchymal stem-like (MSL): Shares features with stem cells and shows a distinct pattern of gene expression related to stem cell characteristics.
5. Immunomodulatory (IM): Enriched for genes involved in immune system function, suggesting a potentially robust immune response against the tumor.
6. Luminal androgen receptor (LAR): Defined by expression of the androgen receptor (AR), a protein that responds to male sex hormones. This subtype has a unique set of characteristics that distinguish it from other TNBC subtypes.

A critical limitation exists here: TNBC molecular subtyping based on mRNA expression levels does not accurately reflect protein expression levels. This discrepancy affects both the efficacy of targeted therapies (since drugs usually act on proteins, not RNA) and the accuracy of prognostic predictions (which rely on understanding what the tumor is actually producing at the protein level). This gap between mRNA and protein — known as a lack of correlation — is a significant ongoing challenge in the field.

The Crucial Role of BRCA1 and BRCA2 Mutations

Of all the genetic players in TNBC, the BRCA genes take center stage. Most (approximately 85%) of TNBC cases develop in the context of BRCA1 germline mutations. Additionally, between 11% and 19% of TNBC cases develop in the context of either BRCA1 or BRCA2 germline mutations. Germline mutations are inherited genetic changes present in every cell of the body, as opposed to somatic mutations that arise only in tumor tissue.

BRCA1 (breast cancer gene 1) and BRCA2 (breast cancer gene 2) are critical in the DNA damage response (DDR) — the cellular machinery that detects and repairs damaged DNA. Germline DNA mutations in BRCA1 or BRCA2 frequently result in a loss of function in DNA repair, leading to an accumulation of genetic errors that can drive cancer development and cell-cycle checkpoint activation.

Notably, when a germline BRCA1 mutation is present, it is more likely to lead to the development of triple-negative breast cancer than to hormone receptor-positive breast cancer. In contrast, germline BRCA2 mutations can lead to a range of breast cancer subtypes, including luminal and TNBC. This highlights the importance of considering both germline and somatic mutations in BRCA1/2 when evaluating breast cancer classification and treatment options.

Somatic mutations in BRCA1 or BRCA2 — mutations that occur during a person's lifetime, are not inherited, and are found only in cancer cells — also contribute to breast cancer classification and treatment decisions. Even without germline BRCA1/2 mutations, alterations in other homologous recombination (HR) genes, such as PALB2, CHEK2, ATM, and NBN, can lead to an increased risk of breast cancer development.

Patients with TNBC and BRCA mutations may benefit from PARP inhibitors, a class of drugs that specifically target cancer cells with DNA repair defects. This is a prime example of how understanding molecular features translates directly into treatment recommendations.

DNA Repair Defects: Homologous Recombination Deficiency

The majority of TNBC cases exhibit a high frequency of homologous recombination (HR) DNA repair deficiency (HRD)-related signatures. Homologous recombination is a carefully orchestrated process cells use to repair double-stranded DNA breaks — some of the most dangerous types of DNA damage. When this pathway is broken, cells must rely on less accurate repair mechanisms, leading to genomic instability that drives cancer development.

Defects in double-stranded DNA repair play a key role in the pathogenesis of TNBC, often due to either germline or somatic mutations in BRCA1 and other genes involved in homologous recombination. The proteins involved in DDR and HR work together in a coordinated fashion:

• Sensors: Detect DNA damage (like ATM)
• Mediators: Relay the damage signal (like BRCA1 and CHK2)
• Effectors: Carry out the repair (like BRCA2 and RAD51)
• Facilitators: Support the HR pathway (like PALB2 and BRIP1)

TNBC is associated with a complex genomic profile, particularly in the basal-like immune-activated subtype. This genomic complexity — including mutations, copy number alterations, and structural rearrangements — creates challenges for treatment but also provides potential therapeutic targets.

Mutations in TP53 and PIK3CA exhibit the highest clonal frequencies in TNBC, suggesting their significant roles in the early stages of TNBC tumorigenesis (the process by which normal cells become cancerous). They are "driver" mutations — genetic changes that directly contribute to cancer development and growth.

The Immune System's Role: Immune-Suppressed vs. Immune-Activated Tumors

Recent advances in research have refined our understanding of TNBC subtypes, leading to the identification of two important categories: basal-like immune-suppressed (BLIS) and basal-like immune-activated (BLIA) subtypes. These subtypes include many basal-like tumors that carry germline and/or somatic BRCA1 mutations.

The BLIS subtype is defined by a specific immune phenotype in which the immune response is suppressed. This contrasts with other TNBC subtypes that may have an activated immune environment. Tumors in the BLIS category essentially "hide" from the immune system, making them less responsive to immunotherapies that rely on an active immune response to target cancer cells.

Recent research emphasizes the modulatory role of microRNAs — small non-coding RNA molecules that regulate gene expression — in TNBC, especially in the basal-like phenotype. These tiny molecules are implicated in the immune suppression observed in BLIS TNBC. Understanding these regulatory mechanisms may open new avenues for targeted therapies that could reverse immune suppression and make these tumors more vulnerable to treatment.

The immune-suppressed nature of BLIS TNBC is linked to the expression of immune checkpoint molecules — proteins on immune cells that act as "off switches." These molecules, including PD-1/PD-L1 and CTLA-4, can inhibit the activation of T-cells (a type of immune cell) against tumor cells. By blocking these inhibitory signals, immunotherapies can potentially reinvigorate the immune system's ability to fight the cancer.

The BLIS subtype generally indicates a poorer prognosis compared to other TNBC subtypes. This is due to the cancer's ability to evade immune detection and the challenges in effectively targeting this subtype with current therapies. However, research into the molecular underpinnings of BLIS TNBC holds promise for developing more effective treatments in the future, such as targeting the pathways responsible for microRNA regulation and immune checkpoint activation.

In contrast, the BL2 subtype shows signs of immune cell infiltration within the tumor microenvironment and may exhibit a higher sensitivity to immunotherapy approaches. Checkpoint inhibitors that target PD-1/PD-L1 and CTLA-4 work by enhancing the body's natural immune response against cancer cells — an approach that may be more effective in immune-active subtypes like BL2.

How TNBC Spreads: The Mesenchymal Subtype

The mesenchymal (M) subtype of TNBC is characterized by a biological process called epithelial-mesenchymal transition (EMT). Normally, epithelial cells (the type of cell that lines ducts and organs, including breast tissue) have tight cell-to-cell adhesion — they stick firmly together. During EMT, cancer cells transform to a mesenchymal state characterized by increased motility and invasiveness.

EMT is a crucial process in cancer metastasis. It allows epithelial cancer cells to acquire mesenchymal characteristics, enabling them to invade surrounding tissue, migrate through the bloodstream or lymphatic system, and eventually form secondary tumors (metastases) in distant organs. In addition, some cells exhibit a hybrid epithelial/mesenchymal (E/M) phenotype — meaning they display both epithelial and mesenchymal traits simultaneously. This dual characteristic may provide cancer cells with the versatility to navigate through different stages of the metastatic process more effectively than cells locked into a single phenotype.

Mesenchymal TNBC tumors typically exhibit enhanced cell motility and invasive properties, which contribute to the cancer's ability to spread to distant organs and tissues. Worryingly, mesenchymal TNBC cells may display resistance to certain chemotherapy regimens and targeted therapies, making this subtype particularly challenging to treat.

Another important concept is the prevalence of breast cancer stem cell (BCSC) populations in TNBC. These cells have stem-like properties, meaning they can self-renew and differentiate, and they are considered a major driver of tumor aggression, treatment resistance, and relapse. BCSC populations are more prevalent in TNBC, particularly in the BL2 and M subtypes, where mesenchymal-like BCSCs were predominantly found. On the other hand, epithelial-like BCSCs were also identified in the BL1 and LAR TNBC subtypes. This distinction suggests that different TNBC subtypes harbor unique BCSC populations, which could contribute to their aggressive tumor features, treatment resistance, tumor relapse, and adverse clinical outcomes.

The LAR Subtype: When Androgen Receptors Drive Cancer

While most breast cancers are driven by estrogen and progesterone receptors, the luminal androgen receptor (LAR) subtype of TNBC relies on a different hormone pathway: the androgen receptor (AR). The defining feature of this subtype is the expression of the androgen receptor in tumor cells. The androgen receptor responds to androgens (male sex hormones, such as testosterone), which significantly influence the growth and progression of this subtype.

Because the androgen receptor is a key driver in LAR TNBC, therapies that target the androgen receptor — such as anti-androgen drugs — may be considered as potential treatments. These drugs aim to block the activity of the androgen receptor, essentially cutting off the fuel supply that drives tumor growth.

LAR TNBC demonstrates a gene expression profile that sets it apart from other TNBC subtypes. In certain respects, it resembles luminal breast cancers, which are typically marked by the presence of hormone receptors. This unique gene expression pattern underscores the distinct nature of the LAR subtype.

One encouraging note: despite being a subtype of TNBC, LAR TNBC tends to have a better prognosis compared to other TNBC subtypes. Additionally, it may respond differently to various treatment strategies, indicating the importance of accurately identifying and categorizing breast cancer subtypes for tailored therapeutic approaches.

Genomic analysis of TNBC reveals that TP53 is the most commonly mutated driver gene, followed by PIK3CA. Other genetic alterations such as PTEN, KMT2C, and RB1 are detected at lower frequencies.

Key Genetic Mutations and Genomic Alterations

The genomic landscape of TNBC involves a complex array of mutations and structural changes. When researchers analyze TNBC genomes, they find recurring patterns of copy number alterations — changes in the number of copies of specific genes or chromosomal regions.

Common genomic alterations in TNBC include:

• Gains of chromosome regions 1q, 8q, and 10q (extra copies of genes in these regions)
• Losses of chromosome regions 5q and 8p (missing genes)
• Amplifications of EGFR and FGFR2 (too many copies of these growth factor receptors)
• Loss of PTEN (a tumor suppressor gene)

The TP53 gene, responsible for encoding the tumor suppressor protein p53, plays a crucial role in regulating the cell cycle and apoptosis (programmed cell death — a natural process where damaged or abnormal cells self-destruct). In TNBC, TP53 mutations are common and are linked to a poorer prognosis. Think of p53 as a "guardian of the genome" — when it's mutated, cells with damaged DNA are allowed to survive and multiply, driving cancer progression.

PTEN is another tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway, which is crucial for cell proliferation and survival. Loss of PTEN function has been observed in a subset of TNBCs, suggesting potential sensitivity to PI3K/AKT pathway inhibitors — another example of how molecular profiling can guide treatment selection.

EGFR (epidermal growth factor receptor) plays a role in cell proliferation and survival, and its overexpression is associated with a more aggressive disease course. Targeted amplification against EGFR is being explored in TNBC.

The basal-like 1 subtype exhibits the highest copy number alterations among TNBC subtypes. Specifically, BL1 tumors feature gains and amplifications in genes like:

• MYC
• PIK3CA
• CDK6
• AKT2
• KRAS
• FGFR1
• IGF1R
• CCNE1
• CDKN2A/B

And deletions in:

• BRCA2
• PTEN
• MDM2
• RB1

Carcinomas with apocrine differentiation (a specific histologic type) exhibit a distinct set of somatic alterations, including mutations in PIK3CA, PIK3R1, and AKT1, indicating that activation of the PI3K pathway plays a crucial role in the molecular pathogenesis of this disease.

PARP Inhibitors: A Targeted Treatment Approach

PARP (poly ADP-ribose polymerase) is a protein that plays a crucial role in DNA repair. PARP inhibitors are a class of drugs that block this repair function, and they take advantage of a concept called "synthetic lethality." Here's how it works:

1. Cancer cells with BRCA1/2 mutations already have defective DNA repair through the homologous recombination pathway.
2. When PARP is also inhibited, the cancer cell loses its backup DNA repair mechanism.
3. The accumulation of unrepaired DNA damage becomes lethal to the cancer cell.
4. Normal cells (with functioning BRCA genes) can survive because they still have working DNA repair pathways.

PARP inhibitors exhibit significant antitumor effects on BRCA1/2-deficient tumors. Among the PARP inhibitors, olaparib and talazoparib are currently approved for treating BRCA-mutated breast cancer, particularly in advanced and metastatic settings. These inhibitors are known for their strong binding affinity to PARP enzymes, leading to effective inhibition of the DNA repair pathway in cancer cells.

Additional PARP inhibitors, including veliparib, are undergoing clinical trials or development. While they share the same basic mechanism of action, there are differences in their pharmacokinetics (how the body absorbs, distributes, and eliminates the drug) and specific targets within the PARP family. These differences can affect dosing, side effects, and effectiveness in different patient populations.

PARP inhibitors represent a prime example of precision medicine in action: they work best in patients whose tumors have specific genetic vulnerabilities, which is why genetic testing for BRCA mutations is now a standard part of TNBC care.

Clinical Implications: What This Means for Patients

The findings from this research have practical implications for refining treatment strategies, particularly in selecting appropriate systemic therapies and integrating traditional treatment modalities like surgery and radiotherapy into comprehensive care plans for TNBC patients. Here are the key takeaways for patients:

• Genetic testing is essential: Because BRCA1/2 mutations are so prevalent in TNBC (85% develop in the context of BRCA1 germline mutations, and 11–19% in the context of BRCA1/BRCA2 germline mutations), genetic counseling and testing should be a standard part of care for TNBC patients. Knowing your BRCA status can open the door to PARP inhibitor therapy.
• Not all TNBC is the same: The six molecular subtypes (BL1, BL2, M, MSL, IM, LAR) behave differently. For example, BL1 tumors may respond better to chemotherapy that targets rapidly dividing cells, while BL2 tumors may be more amenable to immunotherapy. LAR tumors may benefit from anti-androgen drugs.
• Immunotherapy is not universal: The BLIS subtype, with its suppressed immune environment, may not respond well to immunotherapy. Understanding your tumor's immune profile could help guide whether checkpoint inhibitors are likely to be effective.
• Targeted therapy options exist: Beyond chemotherapy, patients with specific mutations may benefit from PARP inhibitors (olaparib, talazoparib) or potentially PI3K/AKT pathway inhibitors if their tumor has PTEN loss or PIK3CA mutations.
• Prognosis varies by subtype: LAR TNBC tends to have a better prognosis than other subtypes, while BLIS TNBC generally indicates a poorer prognosis. This information can help patients and doctors make more informed decisions.

Perhaps most importantly, these findings reinforce the need for personalized medicine — tailoring treatment to each patient's unique tumor biology. The old "one-size-fits-all" approach to breast cancer treatment is rapidly giving way to a more nuanced model where molecular profiling drives therapeutic decisions.

Limitations of Current Knowledge

Despite the significant advances described in this review, important limitations remain:

• mRNA vs. protein disconnect: TNBC molecular subtyping based on mRNA expression levels does not accurately reflect protein expression levels. This affects the efficacy of targeted therapies and the accuracy of prognostic predictions, because drugs act on proteins, not RNA.
• Unclear racial/ethnic differences: It remains unclear if TNBC molecular subtypes are linked to differences in clinical outcomes across races and ethnicities, even though Hispanic and African-American women have a higher proportion of TNBC cases compared to Caucasian women.
• Complexity of immune evasion: While we know that the BLIS subtype suppresses immune responses, the full mechanisms — including how microRNAs regulate this process — are not completely understood. More research is needed to translate these findings into effective therapies.
• Resistance challenges: Mesenchymal TNBC cells display resistance to certain chemotherapy regimens and targeted therapies. Understanding how to overcome this resistance remains an open question.
• Evolving guidelines: Clinical guidelines for managing the axilla (lymph nodes under the arm) in breast cancer patients are still evolving, reflecting the dynamic nature of the field.

Recommendations for Patients

While this research is primarily aimed at advancing medical understanding, it offers actionable insights for patients facing a TNBC diagnosis:

1. Ask about genetic testing: If you've been diagnosed with TNBC, speak with your doctor about BRCA1/BRCA2 genetic testing. This information can guide treatment decisions, especially regarding PARP inhibitor therapy.
2. Seek treatment at a center that offers molecular profiling: Not all hospitals have access to advanced genomic testing. Comprehensive cancer centers are more likely to offer tumor profiling that can identify which TNBC subtype you have and what targeted therapies might work.
3. Discuss clinical trials: Many promising therapies — including new PARP inhibitors like veliparib, anti-androgen drugs for LAR tumors, and immunotherapy combinations — are being tested in clinical trials. Ask your oncologist whether any trials might be appropriate for your situation.
4. Consider immunotherapy questions: If your tumor is immune-activated (like the BL2 subtype), checkpoint inhibitor therapy might be more effective. If it's immune-suppressed (BLIS), your doctor may consider different strategies.
5. Explore the full treatment toolkit: The standard combination of chemotherapy, surgery, and radiotherapy remains the backbone of TNBC treatment. Molecular insights are adding targeted therapies on top of these traditional approaches, not replacing them.
6. Understand your individual risk: Because somatic mutations in genes like PALB2, CHEK2, ATM, and NBN can increase breast cancer risk even without BRCA mutations, family members of TNBC patients may also benefit from genetic counseling.

Knowledge is power when facing a cancer diagnosis. Understanding the molecular complexity of TNBC — including its subtypes and genetic drivers — empowers patients to ask informed questions and participate actively in shared decision-making with their healthcare team.

Frequently Asked Questions

What is triple-negative breast cancer and how is it different from other breast cancers?

Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, so hormone therapy and HER2-targeted drugs do not work. It tends to be more aggressive, with higher risks of recurrence and metastasis. Chemotherapy is the main systemic treatment because TNBC tumors show no response to endocrine therapy.

Should I get genetic testing for BRCA mutations if I have triple-negative breast cancer?

Yes. Most TNBC cases (about 85%) develop in the context of a BRCA1 germline mutation, and 11–19% involve BRCA1 or BRCA2 germline mutations. Genetic counseling and testing should be a standard part of care because knowing your BRCA status can open the door to PARP inhibitor therapy.

What are the six molecular subtypes of triple-negative breast cancer and why do they matter?

The six subtypes are basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), mesenchymal stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR). Each has a different molecular fingerprint, behavior, and potential treatment response. For example, BL1 tumors may respond better to chemotherapy, while LAR tumors may benefit from anti-androgen drugs.

Will immunotherapy work for my triple-negative breast cancer?

It depends on your tumor's immune profile. The basal-like immune-suppressed (BLIS) subtype hides from the immune system and may respond poorly to immunotherapy. In contrast, immune-activated subtypes like BL2 show immune cell infiltration and may be more sensitive to checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4. Talk to your oncologist about your tumor's immune features.

What is the LAR subtype of triple-negative breast cancer and is it less aggressive?

The luminal androgen receptor (LAR) subtype is driven by androgen receptors rather than estrogen or progesterone. It may respond to anti-androgen drugs that block this fuel supply. LAR TNBC tends to have a better prognosis compared to other TNBC subtypes, and it may respond differently to various treatment strategies.

Why might my triple-negative breast cancer be resistant to chemotherapy?

The mesenchymal (M) subtype shows epithelial-mesenchymal transition, increasing cancer cell motility and invasiveness. Mesenchymal TNBC cells may display resistance to certain chemotherapy regimens and targeted therapies. Also, breast cancer stem cell populations, more prevalent in TNBC subtypes like BL2 and M, are considered major drivers of treatment resistance and relapse.

Source Information

This patient-friendly article is based on peer-reviewed research published in the journal Diagnostics.

Original Article Title: "Triple-Negative Breast Cancer: Molecular Particularities Still a Challenge"

Authors: Vlad Bogdan Varzaru, Tania Vlad, Roxana Popescu, Cristian Sebastian Vlad, Aurica Elisabeta Moatar, and Ionut Marcel Cobec

Publication Details: Diagnostics 2024, Volume 14, Issue 17, Article 1875. Published 27 August 2024. DOI: 10.3390/diagnostics14171875

Note: This patient-friendly article is based on peer-reviewed research. The original review article is open access and available under the Creative Commons Attribution (CC BY) license. This summary/translation is intended for educational purposes and should not replace professional medical advice. Patients should consult their healthcare providers regarding any treatment decisions.